Marker Therapeutics (MRKR)
Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.
$1.23
vs last close+0.02 (+2.08%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 23.81% | 3.97M shares | |
|---|---|---|---|
| 35 holders · as of Jun 30, 2026 | |||
| Insiders | 1.95% | 325.4K shares | |
| 1 holder · as of Dec 26, 2024 | |||
| Other | 74.24% | 12.38M shares | |
| remainder | |||
16.67M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
35 holders · 3.97M shares · 4 new positions · 10 increased · 7 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nea Management Company, LLC | 1.63M | 9.75% | 0 | Aug 14, 2026 |
| Blue Owl Capital Holdings LP | 554.3K | 3.32% | 0 | Aug 11, 2026 |
| Vanguard Capital Management LLC | 426.2K | 2.56% | +36.9K | Aug 13, 2026 |
| Aisling Capital Management LP | 325.4K | 1.95% | 0 | Aug 13, 2026 |
| Renaissance Technologies LLC | 249.4K | 1.50% | +74.1K | Aug 13, 2026 |
| Geode Capital Management, LLC | 139.8K | 0.84% | −21.1K | Aug 12, 2026 |
| Advisor Group Holdings, Inc. | 112.6K | 0.68% | +19.5K | Aug 14, 2026 |
| Vanguard Fiduciary Trust Co | 87.3K | 0.52% | 0 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 9.99% | 1.13M | 13G | May 15, 2025 |
| New Enterprise Associates 16, L.P.incl. Forest Baskett, Carmen Chang +7 more | 9.90% | 1.67M | 13D | Nov 17, 2025 |
| Alyeska Investment Group, L.P. | 9.90% | 1.28M | 13G | Nov 14, 2025 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.